State of the Art Papers from the XXXI IACRLD Symposium

Dear Colleagues,

The XXXI Symposium of the International Association for Comparative Research on Leukemia and Related Diseases, IACRLRD, was held in Bologna, Italy, from August 31 to September 2, 2023, with the participation of many leaders in the field of hematological malignancies.

The symposium is always an outstanding event of this association, taking place at various sites worldwide every two years. Physicians, veterinarians, and scientists in basic research are brought together to promote research and improve outcomes in leukemia and related diseases.

The recent COVID-19 pandemic highlighted the importance of networking between researchers in all fields of medicine to promote the sharing of knowledge on the virus, inflammation, and hematological malignancies. Furthermore, the availability of genome sequences in humans and animal species opens up new avenues for comparative research and novel therapeutic approaches.

In addition to conventional treatment strategies, such as chemotherapeutic drugs and radiotherapy, which have now become completely personalized, immunotherapy has become an efficient strategy for treating cancer. Virus transformation of chimeric antigen receptor (CAR) T cells could eliminate cancer cell populations by reinforcing the ability of the host’s immune system to combat against cancer cells or selectively target various types of tumors.

Oncolytic virotherapy (OV) is a new cancer treatment modality using competent or genetically engineered viruses to replicate in tumor cells selectively.

The symposium also provided sessions on the pathogenesis of leukemias and lymphomas, with particular attention paid to its translation into clinical practice.

Several memorial lectures highlighted some of the most significant recent developments in leukemia and biomedicine.

Recent developments in vaccination against tumors or chronic viral diseases, such as HPV or HZV infection, completed the program.

We strongly believe that this symposium left participants with a comprehensive overview of significant recent developments in leukemia and related diseases concerning pathogenesis and novel therapeutic approaches.

This Special Issue will present research papers, reviews, particularly interesting case reports, and state-of-the-art papers from IACRLRD.

Prof. Dr. Ali Bazarbachi
Dr. Claudio Cerchione
Dr. Giovanni Martinelli
Prof. Dr. Giuseppe Saglio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hematology Reports is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• haematological malignancies
• blood disorder
• pulmonary embolism